Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
Debets P, Dreijerink KMA, Engelsman A, Dahele M, Haak HR, Steenaard RV, Kapiteijn E, Corssmit E, Menke-van der Houven van Oordt CW.
Debets P, et al.
Eur J Cancer. 2024 Jan;196:113424. doi: 10.1016/j.ejca.2023.113424. Epub 2023 Nov 10.
Eur J Cancer. 2024.
PMID: 37977106
Free article.
Based on the FIRM-ACT trial published in 2012, guidelines now advise first line systemic treatment with etoposide, cisplatin, doxorubicin and mitotane (EDP-M). The effect of EDP-M on patient survival in clinical practice in the Netherlands is unknown. ...RESULTS: In …
Based on the FIRM-ACT trial published in 2012, guidelines now advise first line systemic treatment with etoposide, cisplatin, doxorubicin an …